Beta Bionics and Zealand Pharma announce positive Phase 2 results of a small trial of the dual-hormone system ahead of the ADA Scientific Sessions.
Type 1 diabetes decision support technology analyzes patient data from variety of devices to determine insulin delivery recommendations for maintaining balanced glucose levels.
Nemaura plans to initially market the SugarBEAT patch CGM, which has predictive glucose alarms, to people with type 2 diabetes.
The medtech company unveiled CareLink data showing that the automated basal delivery feature of the pump system helped people with type 1 diabetes experience improved Time in Range.
The trial is being conducted by Beta Bionics and Zealand Pharma, and marks the first full-scale test of the dual-hormone therapy in a real-world setting.
Senseonics announced a distribution partnership with a verified Service-Disabled Veteran-Owned Small Business to offer the implantable CGM through the Veterans Health Administration.
The statement has reportedly been endorsed and co-written by key members of the Loop, OpenAPS, and AndroidAPS movements.
The agency says it has received word of an accidental insulin overdose that occurred with an automated insulin dosing system.
How Lonny Stormo’s frustration with meter design led to the creation of POPS! Diabetes Care, and a meter that is elegant enough to double as an iPhone case.
RileyLink founder Pete Schwamb has released the code for others in the #WeAreNotWaiting movement to test run.